Close menu




Biotech

Photo credits: pixabay.com

Commented by Armin Schulz on October 3rd, 2025 | 07:05 CEST

BioNxt Solutions' pharmaceutical revolution: New ways of administering blockbuster drugs

  • Biotechnology
  • Innovations
  • Biotech
  • Pharma

Imagine chemotherapy without severe side effects or a blockbuster drug without needles. What sounds like a pipe dream is now becoming reality thanks to innovative drug delivery systems. They are revolutionizing billion-dollar markets from oncology to obesity therapy and laying the foundation for exponential growth. For investors, this technological breakthrough opens up a unique investment window. BioNxt Solutions is at the forefront of this movement.

Read

Commented by André Will-Laudien on October 2nd, 2025 | 07:25 CEST

AI fuels cancer research: Bayer, Vidac Pharma, and Pfizer are the next 150% winners

  • AI
  • Biotechnology
  • Biotech
  • Pharma

The stock market remains strong! In addition to the tech and defense boom, the biotech sector has also been catching up in recent days, with the latest news in cancer research bringing the industry back into the spotlight. The key factor here is artificial intelligence, which is revolutionizing cancer research through personalized therapy approaches based on the evaluation of extensive clinical and genetic data. AI models make it possible to predict individual cancer progression better and tailor therapies to individual patients. By analyzing multimodal data, AI systems can more accurately assess the risk of metastasis and thus develop targeted treatment strategies. AI has also improved tumor diagnostics by accurately detecting numerous types of cancer, therefore ensuring a more precise diagnosis.

Read

Commented by Carsten Mainitz on October 2nd, 2025 | 07:10 CEST

NetraMark Holdings, Evotec, Sartorius – Billion-dollar deals in sight!

  • Biotechnology
  • Biotech
  • AI
  • Pharma

Artificial intelligence and machine learning have become key drivers across nearly every industry. When pharmaceutical companies successfully develop a drug to market readiness, profits can surge. However, only a few active ingredients that enter clinical trials ultimately receive approval. It is therefore a long, risky, and costly process. The use of AI can help to minimize these risks significantly. Here, we take a look at the potential of AI-based strategies among established players Evotec and Sartorius, with a particular focus on the innovative approach of Canadian company NetraMark Holdings.

Read

Commented by Carsten Mainitz on September 30th, 2025 | 07:40 CEST

Antimony Resources, Rheinmetall, Novo Nordisk – Something is in the air!

  • Mining
  • antimony
  • Defense
  • Biotechnology

Sufficient access to raw materials is crucial for any economy. The EU has compiled a list of 34 critical raw materials. How critical a raw material is classified depends on two parameters: "economic importance" and "supply risk." This list also includes a little-known but very important metalloid – antimony. The price of antimony skyrocketed at the end of 2024 in the wake of China's export ban. There are still exciting investment opportunities in this area.

Read

Commented by André Will-Laudien on September 30th, 2025 | 07:35 CEST

High-tech super boom! 1,000% no problem—here is more from D-Wave, NetraMark and Palantir!

  • Biotechnology
  • AI
  • Digitization
  • hightech
  • computing
  • Software

Artificial intelligence (AI) is currently revolutionizing drug development by analyzing enormous amounts of data in a very short time and making clinical trials much more targeted. Modern AI systems make it possible to select drug candidates with precision and predict the potential success of a therapy with a high degree of accuracy. Companies like NetraMark are already using these technologies profitably. Players such as D-Wave and Palantir are also among the pioneers of the new AI-driven economy and have seen their share prices rise by over 1,000%. Expectations for further growth are virtually limitless. The advent of quantum computer technology also marks the beginning of a new chapter in ultra-fast data processing. For forward-looking investors, this opens up attractive entry opportunities in dynamically expanding future markets. Those who bet on the right players early on can benefit from this change to an above-average extent.

Read

Commented by André Will-Laudien on September 29th, 2025 | 07:20 CEST

Attention: Acquisitions! Biotechs like Evotec, PanGenomic Health, Pfizer, and BioNTech in focus

  • Biotechnology
  • Biotech
  • Healthcare
  • healthtech

The biotech industry is in turmoil! With the expiration of blockbuster patents, there is a threat of sharp declines in revenue, which must be strategically compensated for. Driven by economic pressure and a growing focus on innovation and technology, the industry is increasingly turning to acquisitions of biotech companies with promising drug candidates, new technologies, and digital expertise. Not only are entire pipelines being acquired, but key players from the fastest-growing segments are also being targeted, particularly in the field of obesity therapies, where billions are being paid for drug candidates. Several examples illustrate this wave of transformation. Companies are restructuring, focusing their activities, and rapidly preparing for a phase of sustainable growth. The pace is picking up! Here are some promising investment ideas!

Read

Commented by Fabian Lorenz on September 29th, 2025 | 07:00 CEST

Takeover in the Ozempic market! BioNxt Solutions next? Novo Nordisk, Eli Lilly, and Pfizer are fighting!

  • Biotechnology
  • Biotech
  • Pharma

The battle against obesity is considered one of the biggest growth markets in the global pharmaceutical sector. According to estimates, the market for obesity therapies could reach a volume of up to USD 150 billion by 2030. So far, Novo Nordisk and Eli Lilly have dominated the market. But almost every major corporation and innovative challenger wants a piece of the pie. The latest example: Pfizer is planning a billion-dollar takeover of US-based Metsera, a company competing with novel drugs against obesity. BioNxt Solutions is also a hot takeover candidate. The Company aims to revolutionize the market and attract new customers with an oral dosage form, and the first prototypes have already been developed. That makes it an attractive prospect for virtually every pharmaceutical company.

Read

Commented by Nico Popp on September 26th, 2025 | 07:30 CEST

AI is conquering increasingly more areas: SAP and Amazon are targeting small and mid-sized businesses, while NetraMark is winning over the biotech industry

  • Biotechnology
  • Biotech
  • AI
  • Technology
  • Innovations

Will AI become our new god? This question is currently being explored in depth by the German philosopher Markus Gabriel in a well-known German podcast. And although the question may cause unease for many, Gabriel's conclusions are ultimately anything but pessimistic. SAP and Amazon are also looking to the future with optimism: Together with OpenAI, they are now building an AI infrastructure in Germany. The goal: to enable public authorities and companies to use the latest AI tools in a legally compliant manner, without European data leaving the continent. The initiative demonstrates that AI will conquer many more areas in the coming years. One of these areas is medical research. The innovative company NetraMark is using its AI solution to deliver faster results and lower costs for future-focused projects, such as the fight against cancer.

Read

Commented by André Will-Laudien on September 26th, 2025 | 07:15 CEST

BioNxt Solutions – Biotech specialist with significant leverage in mega markets

  • Biotechnology
  • Biotech
  • Pharma

Modern medicine faces an enormous challenge: More and more people are suffering from so-called diseases of affluence, such as obesity, diabetes, multiple sclerosis, and MASH, the dreaded fatty liver disease. At the same time, there is a growing need for innovative therapies and new dosage forms that make treatments more effective, simpler, and more patient-friendly. This is precisely where BioNxt Solutions comes in, a young biotech company that is addressing several billion-dollar markets with its patented thin-film technology. By enabling the oral administration of important active ingredients such as semaglutide and cladribine, BioNxt is not only opening up new therapeutic avenues but also significantly enhancing the effectiveness of existing drugs. At a time when pharmaceutical giants are investing billions in new solutions, BioNxt could become one of the most exciting future players in the industry.

Read

Commented by Nico Popp on September 23rd, 2025 | 07:00 CEST

What MASH could do for your portfolio: BioNxt, Roche, Novo Nordisk

  • Biotechnology
  • Biotech
  • Pharma

Have you heard of MASH? The acronym stands for metabolic-associated steatohepatitis, which was previously simply called "fatty liver." Medications targeting this disease, which studies suggest affects around 6% of Americans, are being hailed as the next big trend in the biotech market. Overall, one in three overweight individuals is affected. Since many patients initially show no symptoms, MASH is considered particularly insidious. The growing discussion around the condition could turn many at-risk individuals into patients who take medication, which is excellent news for certain companies in the sector. For a small-cap stock, the hype surrounding MASH could even be transformative.

Read